MA-PD vs Medigap for a Traveling Beneficiary With COPD
Ruth is 71, has COPD and type 2 diabetes, and has been in a Medicare Advantage-PD plan for four years. Her plan has a $0 premium, a $4,900 in-network out-of-pocket maximum, and an $8,000 combined in/out-of-network maximum. She sees a pulmonologist every eight weeks and takes five Part D drugs. From January through March she stays with her daughter in another state; during those months she needs routine follow-up and lab work, not emergency care. Ruth’s income is $2,800 per month, and she has $30,000 in savings. A Medigap Plan G policy in her county costs $210 per month and would require medical underwriting because she is past her Medigap open enrollment period. Ruth asks whether switching to Original Medicare plus Plan G and a standalone Part D plan is worth it, and what happens if she is declined.
1. Compare the two paths for Ruth’s three-month stay and her chronic conditions. What is the key product risk in each?
Read the worked answer
At home, the MA-PD is cheaper in fixed premiums and gives her an in-network care team. The travel issue is the weak point: routine follow-up and labs in another state may be out-of-network, and even a PPO with a combined $8,000 maximum can leave substantial cost sharing. Original Medicare plus Plan G travels with her to any Medicare-participating provider and makes costs predictable after the Part B deductible, but adds a $210 monthly premium plus a standalone Part D premium and formulary checks. The key risk on the MA side is network and travel access; the key risk on the Medigap side is medical underwriting and affordability. Because her COPD is stable but chronic, the answer depends less on benefits and more on whether she can qualify for Plan G.
2. Before recommending the switch, what should the agent verify about Ruth’s Medigap rights and Part D? Give the decision rule.
Read the worked answer
Do not promise Plan G. She is past her Medigap open enrollment period and has been in MA for three years, so the federal 12-month MA trial right likely does not apply. In most states the insurer can underwrite; COPD may lead to a decline, a higher premium, or exclusion. Check state-specific guaranteed-issue or birthday rules, but treat them as exceptions. Verify that a standalone Part D plan covers all five drugs and that the total annual fixed cost is sustainable. If she cannot qualify for Plan G, the fallback is to optimize an MA-PD, preferably a PPO or one with a broad national network, and plan routine care around her travel. A Medigap application should not be submitted until she understands the underwriting outcome and the Part D formulary.